checkAd
    Startseite > Aktien > Intellia Therapeutics > Nachrichten
    Intellia Therapeutics Aktie
    19,710
     
    EUR
    -3,33 %
    -0,680 EUR
    Letzter Kurs 31.05.24 Tradegate
    19,490
     
    EUR
    307 STK
    Geldkurs 31.05.24
    19,790
     
    EUR
    303 STK
    Briefkurs 31.05.24
    ISIN: US45826J1051 · WKN: A2AG6H · SYM: 38I · USA

    Neueste Nachrichten

    Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
    09.05.24 · globenewswire · Intellia Therapeutics
    Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates
    02.05.24 · globenewswire · Intellia Therapeutics
    Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024
    29.04.24 · globenewswire · Intellia Therapeutics
    Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy
    18.03.24 · globenewswire · Intellia Therapeutics
    Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress
    22.02.24 · globenewswire · Intellia Therapeutics
    Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis
    15.02.24 · Business Wire (engl.) · Intellia Therapeutics
    Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis
    15.02.24 · globenewswire · Intellia Therapeutics
    Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company Updates
    14.02.24 · globenewswire · Intellia Therapeutics
    Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine
    31.01.24 · globenewswire · Intellia Therapeutics
    Intellia Therapeutics Highlights its Three-Year Strategic Priorities and Anticipated 2024 Key Milestones
    04.01.24 · globenewswire · Intellia Therapeutics
    Intellia Therapeutics Receives European Union Orphan Drug Designation for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema
    14.11.23 · globenewswire · Intellia Therapeutics
    Intellia Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
    09.11.23 · globenewswire · Intellia Therapeutics